Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors' reply.
Borque-Fernando A, Calleja-Hernández MA, Cózar-Olmo JM, Gómez-Iturriaga A, Pérez-Fentes DA, Puente-Vázquez J, Rodrigo-Aliaga M, Unda M, Álvarez-Ossorio JL. Borque-Fernando A, et al. Among authors: calleja hernandez ma. Actas Urol Esp (Engl Ed). 2023 Jul-Aug;47(6):392-393. doi: 10.1016/j.acuroe.2023.04.014. Epub 2023 Jun 8. Actas Urol Esp (Engl Ed). 2023. PMID: 37301369 English, Spanish. No abstract available.
A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer.
Borque-Fernando A, Calleja-Hernández MA, Cózar-Olmo JM, Gómez-Iturriaga A, Pérez-Fentes DA, Puente-Vázquez J, Rodrigo-Aliaga M, Unda M, Álvarez-Ossorio JL. Borque-Fernando A, et al. Actas Urol Esp (Engl Ed). 2023 Mar;47(2):111-126. doi: 10.1016/j.acuroe.2022.12.004. Epub 2023 Jan 28. Actas Urol Esp (Engl Ed). 2023. PMID: 36720305 English, Spanish.
A cost-effectiveness analysis of empagliflozin for heart failure patients across the full spectrum of ejection fraction in Spain: combined results of the EMPEROR-Preserved and EMPEROR-Reduced trials.
García-Moll X, Croci F, Solé A, Hartgers-Gubbels ES, Calleja-Hernández MA. García-Moll X, et al. Among authors: calleja hernandez ma. Expert Rev Cardiovasc Ther. 2024 Jan-Mar;22(1-3):131-139. doi: 10.1080/14779072.2024.2324027. Epub 2024 Feb 29. Expert Rev Cardiovasc Ther. 2024. PMID: 38416135
Factors Contributing to Negative Outcomes Associated with Medications and Drug-Related Problems in Kidney Replacement Therapy-A Hospital-Based Prospective Observational Study.
Pereira-Céspedes A, Jiménez-Morales A, Polo-Moyano A, Palomares-Bayo M, Martínez-Martínez F, Calleja-Hernández MÁ. Pereira-Céspedes A, et al. Among authors: calleja hernandez ma. J Clin Med. 2024 Feb 12;13(4):1048. doi: 10.3390/jcm13041048. J Clin Med. 2024. PMID: 38398360 Free PMC article.
[Translated article] Consensus recommendations on the preventive treatment of migraine.
Calleja-Hernández MÁ, Guerrero-Peral ÁL, Irimia-Sieira P, Martínez-López I, Santos-Lasaosa S, Sarobe-Carricas M, López-Matencio JMS, Láinez-Andrés JM. Calleja-Hernández MÁ, et al. Farm Hosp. 2023 Nov-Dec;47(6):T246-T253. doi: 10.1016/j.farma.2023.07.002. Epub 2023 Sep 18. Farm Hosp. 2023. PMID: 37730507 Free article. English, Spanish.
Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer: A Systematic Review of Trials Published Between 2010 and 2020.
García-Fumero R, Fernández-López C, Calleja-Hernández MÁ, Expósito-Ruiz M, Espín J, Expósito-Hernández J. García-Fumero R, et al. Among authors: calleja hernandez ma. Am J Clin Oncol. 2023 Oct 1;46(10):433-438. doi: 10.1097/COC.0000000000001031. Epub 2023 Jul 31. Am J Clin Oncol. 2023. PMID: 37522643
118 results